In a recent RESCUE trial, the IL-6 ligand monoclonal antibody ziltivekimab was highly effective at reducing the inflammatory response and atherosclerotic biomarkers, suggesting that IL-6 has become a new therapeutic target for atherosclerosis [37]. Here, IL6 is linked to atherosclerosis.